In this article, we describe the hcost program for estimating mean health care costs and incremental cost-effectiveness ratios with possibly censored data. hcost estimates the mean survival time and the mean costs, as well as their variances and covariance, for a given time horizon. If the group variable is specified, hcost will report the differences between two groups, as well as the incremental cost-effectiveness ratio and its confidence interval (optional). hcost can estimate the mean costs using two methods corresponding to different types of data: the Bang and Tsiatis (2000, Biometrika 87: 329–343) estimator using only the total costs or the Zhao and Tian (2001, Biometrics 57: 1002–1008) estimator when cost-history data are available. The hcost program can also be used to specify the annual discounting rates for survival time and costs.
BangH., and TsiatisA. A.2000. Estimating medical costs with censored data. Biometrika87: 329–343.
2.
BriggsA. H., MooneyC. Z., and WonderlingD. E.1999. Constructing confidence intervals for cost-effectiveness ratios: An evaluation of parametric and non-parametric techniques using Monte Carlo simulation. Statistics in Medicine18: 3245–3262.
3.
EfronB., and TibshiraniR. J.1986. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Statistical Science1: 54–75.
4.
EfronB., and TibshiraniR. J.1993. An Introduction to the Bootstrap.New York: Chapman & Hall/CRC.
5.
FenwickE., MarshallD. A., LevyA. R., and NicholG.2006. Using and interpreting cost-effectiveness acceptability curves: An example using data from a trial of management strategies for atrial fibrillation. BMC Health Services Research6: 52.
6.
FiellerE. C.1954. Some problems in interval estimation. Journal of the Royal Statistical Society, Series B16: 175–185.
7.
GoldM. R., SiegelJ. E., RussellL. B., and WeinsteinM. C.1996. Cost-effectiveness in Health and Medicine.New York: Oxford University Press.
8.
HuangY.2002. Calibration regression of censored lifetime medical cost. Journal of the American Statistical Association97: 318–327.
9.
HwangJ. T. G.1995. Fieller's problems and resampling techniques. Statistica Sinica5: 161–171.
10.
JiangG., WuJ., and WilliamsG. R.2000. Fieller's interval and the bootstrap-Fieller interval for the incremental cost-effectiveness ratio. Health Services and Outcomes Research Methodology1: 291–303.
11.
JiangH., and ZhouX.-H.2004. Bootstrap confidence intervals for medical costs with censored observations. Statistics in Medicine23: 3365–3376.
12.
KimL. G., and ThompsonS. G.2011. Estimation of life-years gained and cost effectiveness based on cause-specific mortality. Health Economics20: 842–852.
13.
LinD. Y., FeuerE. J., EtzioniR., and WaxY.1997. Estimating medical costs from incomplete follow-up data. Biometrics53: 419–434.
14.
LöthgrenM., and ZethraeusN.2000. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Economics9: 623–630.
15.
MushlinA. I., HallW. J., ZwanzigerJ., GajaryE., AndrewsM., MarronR., ZouK. H., MossA. J., and for the MADIT Investigators. 1998. The cost-effectiveness of automatic implantable cardiac defibrillators: Results from MADIT. Circulation97: 2129–2135.
16.
O'BrienB. J., and BriggsA. H.2002. Analysis of uncertainty in health care cost-effectiveness studies: An introduction to statistical issues and methods. Statistical Methods in Medical Research11: 455–468.
17.
PfeiferP. E., and BangH.2005. Non-parametric estimation of mean customer lifetime value. Journal of Interactive Marketing19: 48–66.
18.
SattenG. A., and DattaS.2001. The Kaplan-Meier estimator as an inverse-probability-of-censoring weighted average. American Statistician55: 207–210.
19.
StinnettA. A., and MullahyJ.1998. Net health benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis. Medical Decision Making18: S68–S80.
20.
WangH., and ZhaoH.2008. A study on confidence intervals for incremental cost-effectiveness. Biometrical Journal50: 505–514.
21.
WillanA. R., LinD. Y., and MancaA.2005. Regression methods for cost-effectiveness analysis with censored data. Statistics in Medicine24: 131–145.
22.
ZhaoH., BangH., WangH., and PfeiferP. E.2007. On the equivalence of some medical cost estimators with censored data. Statistics in Medicine26: 4520–4530.
23.
ZhaoH., and TianL.2001. On estimating medical cost and incremental cost-effectiveness ratios with censored data. Biometrics57: 1002–1008.
24.
ZhaoH., and TsiatisA. A.1997. A consistent estimator for the distribution of quality adjusted survival time. Biometrika84: 339–348.
25.
ZhaoH., and TsiatisA. A.1999. Efficient estimation of the distribution of quality-adjusted survival time. Biometrics55: 1101–1107.
